VIDEO: Trial explores novel TKI plus PD-1 inhibitor for non-clear cell renal cell carcinoma
Click Here to Manage Email Alerts
MADRID — In a video interview with Healio, Sumanta (Monty) Pal, MD, FASCO, spoke about the STELLAR-304 clinical trial for patients with non-clear cell renal cell carcinoma at ESMO Congress.
Non-clear cell kidney cancer “really doesn’t get the attention that it deserves,” according to Pal, co-director of City of Hope’s Kidney Cancer Program, HemOnc Today Editorial Board Member and member of the Kidney Cancer Association's Medical Steering Committee.
“We’ve really never had a successful phase 3 study in this setting — really hoping to change that,” Pal said.
The study will look at the efficacy and safety of the novel tyrosine kinase inhibitor zanzalintinib (XL092, Exelixis) plus nivolumab (Opdivo, Bristol Myers Squibb) vs. sunitinib (Sutent, Pfizer), the standard of care in this setting, in first-line non-clear cell kidney cancer.
Collapse
Pal S, et al. Abstract 1912TiP. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Click Here to Manage Email Alerts